GW’s cannabinoid fails in focal seizures trial

22nd February 2018 Uncategorised 0

A mid-stage trial assessing an experimental cannabinoid being developed by GW Pharma for adults with focal seizures has failed to hit key targets.

More: GW’s cannabinoid fails in focal seizures trial
Source: News